BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37013251)

  • 21. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Zeng Q; Xiang B; Liu Z
    Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
    Zhou M; Sha X; Qiu H; He G; Xu Y; Cen J; Pan J; Chen S; Sun A; Zhang R; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):126-8. PubMed ID: 24606653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy of allogeneic hematopoietic stem cell transplantation in treatment of childhood myelogenous leukemia: the observation of 24 cases].
    Sun Y; Sun RJ; Wei ZJ; Xiao J; Zhang YC; Gao YQ; Zhu HL
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):813-6. PubMed ID: 23302609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia].
    Jiang H; Hu WT; Chen J; Luo CY; Wang JM; Zhou M; Ye QD; Tang YJ; Luo CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jan; 15(1):19-24. PubMed ID: 23336162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
    Zhang GF; Zhou M; Bao XB; Qiu HY; Li Z; Xue SL
    Asian Pac J Cancer Prev; 2016; 17(9):4477-4481. PubMed ID: 27797264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of advanced-phase chronic myeloid leukemia].
    Kitanaka A
    Rinsho Ketsueki; 2016; 57(10):1962-1971. PubMed ID: 27725594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
    Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
    Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.
    Chaudhury S; Sparapani R; Hu ZH; Nishihori T; Abdel-Azim H; Malone A; Olsson R; Hamadani M; Daly A; Bacher U; Wirk BM; Kamble RT; Gale RP; Wood WA; Hale G; Wiernik PH; Hashmi SK; Marks D; Ustun C; Munker R; Savani BN; Alyea E; Popat U; Sobecks R; Kalaycio M; Maziarz R; Hijiya N; Saber W
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1056-1064. PubMed ID: 26964698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT.
    Masouridi-Levrat S; Olavarria E; Iacobelli S; Aljurf M; Morozova E; Niittyvuopio R; Sengeloev H; Reményi P; Helbig G; Browne P; Ganser A; Nagler A; Snowden JA; Robin M; Passweg J; Van Gorkom G; Wallet HL; Hoek J; Blok HJ; De Witte T; Kroeger N; Hayden P; Chalandon Y; Agha IY
    Bone Marrow Transplant; 2022 Jan; 57(1):23-30. PubMed ID: 34599284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
    Poiré X; Artz A; Larson RA; Kline J; Odenike O; Rich E; Godley L; Stock W; van Besien K
    Leuk Lymphoma; 2009 Jan; 50(1):85-91. PubMed ID: 19142796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
    Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation].
    Chen Y; Xu Y; Zhu Y; Fu G; Liu Y; Peng J; Fu B; He Q; Wu D; Li X; Zhao X; Chen F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):859-64. PubMed ID: 21946205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse].
    Xu LP; Liu KY; Huang XJ; Liu DH; Han W; Chen YH; Wang Y; Liu YR; Qin YZ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):522-5. PubMed ID: 19112914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of children with chronic myeloid leukemia: A population-based cohort study.
    Egan G; Athale U; Johnston D; Pole JD; Silva M; Zorzi A; Alexander S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28491. PubMed ID: 32589368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases].
    He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Molecular or Cytogenetic Response as a Favorable Prognostic Factor Before Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.
    Medeiros GRO; Funke VAM; Lima ACM; Mion ALV; Menezes I; Setubal DC; Sola CBDS; Tagliari G; Marchesini R; Nabhan SK; Pasquini R
    Transplant Cell Ther; 2024 Jun; 30(6):597.e1-597.e8. PubMed ID: 38522578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.